The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-15. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
=== Fold switching === Some proteins have multiple native structures, and change their fold based on some external factors. For example, the KaiB protein switches fold throughout the day, acting as a clock for cyanobacteria. It has been estimated that around 0.5–4% of PDB (Protein Data Bank) proteins switch folds.
Even though as of March 2025 they still pushed for buyout in July they abandoned the bid. On March 6, 2025, 7-Eleven's parent company Seven & I Holdings announced that it would spin off the US store operations into its own publicly traded entity by the end of 2026, following the announcement of the appointment of its first foreign CEO Stephen Hayes Dacus.
By the end of the Cold War, the Soviet Armed Forces maintained the world's largest arsenals of nuclear, chemical, and biological weapons. As dissolution seemed imminent, the United States initiated the Nunn–Lugar Cooperative Threat Reduction program to dismantle much of this Soviet infrastructure and secure its personnel and materials. The Soviet Union had the largest nuclear weapons arsenal ever, peaking at over 40,000 warheads in 1986. The country was the second to develop nuclear weapons, conducting its first test RDS-1 in 1949, four years after the US Trinity test. Its primary nuclear testing sites were Semipalatinsk, Novaya Zemlya, and Kapustin Yar. By 1991, it deployed over 10,000 strategic nuclear weapons in its nuclear triad: Strategic Rocket Forces' silo-based and road-mobile intercontinental ballistic missiles, the Soviet Navy's submarine-launched ballistic missiles, and Long Range Aviation's Tu-95MS and Tu-160 bombers. Another 11,000 tactical nuclear weapons were assigned to land and naval tactical aircraft, missiles, nuclear artillery, and anti-submarine weapons. The Soviet chemical weapons program became the largest in world history. Russia in 1993 declared 39,967 tons of chemical weapons. The program produced Novichok, VR, sarin, and soman nerve agents, as well as lewisite, mustard, and phosgene, and others. By comparison, 27,770 metric tons were declared for the United States chemical weapons program in 1997. By the time of the Soviet Union's dissolution in 1991, its research institute, GosNIIOKhT, employed around 6,000 people across Russia and Uzbekistan.
Sources: en.wikipedia.org
TNFR provides specificity for the drug target and the antibody Fc segment is believed to add stability and deliverability of the drug. Additional chimeric proteins used for therapeutic applications include:
Hydrodynamic theories describe liquids in terms of space- and time-dependent macroscopic fields, such as density, velocity, and temperature. These fields obey partial differential equations, which can be linear or nonlinear. Hydrodynamic theories are more general than equilibrium thermodynamic descriptions, which assume that liquids are approximately homogeneous and time-independent. The Navier-Stokes equations are a well-known example: they are partial differential equations giving the time evolution of density, velocity, and temperature of a viscous fluid. There are numerous methods for numerically solving the Navier-Stokes equations and its variants.
On 14 January, the United States Department of Energy announced that the United States had completed their first sales of Venezuelan oil valued at $500 million as part of a $2 billion deal between United States and Venezuela governments. On 15 January, Delcy Rodríguez announced that she was submitting a reform to the country's hydrocarbon law to "allow [foreign] investment flows to be incorporated into new fields, fields where no investment has ever been made and into fields where there is no infrastructure"; On 20 January, Delcy Rodríguez confirmed having received the first $300 million. She announced the money will go to the exchange market in Venezuela, the national banks and the central bank. Reuters indicated that the remaining $200 million were returned on 3 February according to anonymous United States officials. The proceeds from the sales were deposited in a Qatari bank account, preventing Venezuela's creditors from seizing them. Democrats questioned the legality of this arrangement, and criticized the lack of transparency in routing the funds. On 23 January, the first cargo of 460,000 barrels of naphtha by Vitol, necessary to deal with the heavy crude oil, arrived to Venezuela in a deal with the United States. Before that last cargo was received in December 2025 by Chevron Corporation in an agreement with the United States as the naval blockade had stopped many suppliers. On 28 January, Delcy Rodríguez announced that the United States was unfreezing various funds related to 2019 oil sanctions on Venezuela.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.